Exscientia Yönetim
Yönetim kriter kontrolleri 1/4
Exscientia's CEO is Dave Hallett, appointed in Feb 2023, has a tenure of 1.75 years. directly owns 0.001% of the company’s shares, worth $7.35K. The average tenure of the management team and the board of directors is 1.8 years and 3.9 years respectively.
Anahtar bilgiler
Dave Hallett
İcra Kurulu Başkanı
n/a
Toplam tazminat
| CEO maaş yüzdesi | n/a |
| CEO görev süresi | 1.8yrs |
| CEO sahipliği | 0.001% |
| Yönetim ortalama görev süresi | 1.8yrs |
| Yönetim Kurulu ortalama görev süresi | 3.9yrs |
Son yönetim güncellemeleri
Recent updates
Recursion's Acquisition Of Exscientia Makes Sense On Some Levels, Not Others
Aug 08Here's Why We're Watching Exscientia's (NASDAQ:EXAI) Cash Burn Situation
Jul 17
Exscientia: Too Much Pessimism
Jun 10Exscientia: Drug Discovery Platform Attracting Partners And Cash
May 22Exscientia: A Strategic Hold In The AI-Driven Drug Discovery Sector (Rating Downgrade)
Feb 26Is Exscientia (NASDAQ:EXAI) In A Good Position To Invest In Growth?
Jan 11Earnings Update: Exscientia plc (NASDAQ:EXAI) Just Reported Its Third-Quarter Results And Analysts Are Updating Their Forecasts
Nov 12New Forecasts: Here's What Analysts Think The Future Holds For Exscientia plc (NASDAQ:EXAI)
Aug 31We're Keeping An Eye On Exscientia's (NASDAQ:EXAI) Cash Burn Rate
Aug 25Broker Revenue Forecasts For Exscientia plc (NASDAQ:EXAI) Are Surging Higher
Jul 21Exscientia (NASDAQ:EXAI) Is In A Good Position To Deliver On Growth Plans
Apr 22We're Not Very Worried About Exscientia's (NASDAQ:EXAI) Cash Burn Rate
Dec 30The Exscientia plc (NASDAQ:EXAI) Analysts Have Been Trimming Their Sales Forecasts
Aug 31Exscientia: Using AI To Power Drug Development
Aug 15Companies Like Exscientia (NASDAQ:EXAI) Can Afford To Invest In Growth
May 29Exscientia: Drug Discovery Using AI For Sanofi And Self-Owned Pipeline
Apr 12Bullish: Analysts Just Made A Sizeable Upgrade To Their Exscientia plc (NASDAQ:EXAI) Forecasts
Jan 09CEO
Dave Hallett (55 yo)
1.8yrs
Görev süresi
Dr. David Hallett, also known as Dave, Ph.D. is the Chief Operations Officer of Exscientia Limited since January 2020. He served as Chief Operating Officer at Exscientia plc since June 2022 until 2022 and...
Liderlik Ekibi
| İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
|---|---|---|---|---|
| Chief Scientific Officer | 1.8yrs | Veri yok | 0.0012% $ 7.3k | |
| CFO, Chief Strategy Officer & Executive Director | 4yrs | UK£1.92m | 0.062% $ 392.2k | |
| Chief Technology Officer | less than a year | Veri yok | 0.015% $ 96.0k | |
| Vice President of Investor Relations | no data | Veri yok | Veri yok | |
| Executive VP of Legal & Company Secretary | 1.8yrs | Veri yok | Veri yok | |
| Executive Vice President of Corporate Development | less than a year | Veri yok | Veri yok | |
| Chief People Officer | 2.2yrs | Veri yok | Veri yok | |
| Chief Business Officer | no data | Veri yok | Veri yok | |
| Executive Vice President of Precision Medicine | 1.8yrs | Veri yok | Veri yok | |
| Interim Chief Medical Officer & Clinical Development Lead | less than a year | Veri yok | Veri yok |
1.8yrs
Ortalama Görev Süresi
55yo
Ortalama Yaş
Deneyimli Yönetim: EXAI's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.
Yönetim Kurulu Üyeleri
| İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
|---|---|---|---|---|
| Chief Scientific Officer | less than a year | Veri yok | 0.0012% $ 7.3k | |
| CFO, Chief Strategy Officer & Executive Director | 4yrs | UK£1.92m | 0.062% $ 392.2k | |
| Independent Non-Executive Chairman | 3.8yrs | UK£282.03k | 0.089% $ 564.4k | |
| Independent Non-Executive Director | 7.2yrs | UK£201.69k | 0.053% $ 334.4k | |
| Independent Non-Executive Director | 4.5yrs | Veri yok | Veri yok | |
| Independent Director | 1.5yrs | UK£178.86k | 0.028% $ 177.9k |
3.9yrs
Ortalama Görev Süresi
51yo
Ortalama Yaş
Deneyimli Yönetim Kurulu: EXAI's board of directors are considered experienced (3.9 years average tenure).